MYC and neoplasm: Since sorafenib is the first-line drug approved by FDA, we compared the anti-tumor effect of JQ1 with sorafenib, showing that JQ1 had more promising anti-tumor effects than sorafenib in HCC cells expressing relatively high level of MYC in vitro and in vivo.